E-nose detects malignant mesothelioma

August 2, 2012

Australian researchers have developed a breath test using an electronic nose to help diagnose malignant mesothelioma in its early stages, a potentially life-saving move.

The non-invasive test was created by a team at the University of . The device was designed to distinguish between benign and malignant and to detect disease early.

“If you catch it earlier your chances of actually giving people the right treatment to stop it spreading are actually better,” says study team leader, Associate Professor Deborah Yates, from UNSW's St Vincent's Clinical School.

“We tried to exclude the other asbestos diseases because it’s very important from a patient’s point of view that you don’t pick up something that is a benign asbestos disease, so that you don’t diagnose them with something that’s not actually a problem.”

Asbestos-related disease affects thousands of people in Australia, which has one of the highest age-specific rates of mesothelioma in the world.

is a rare tumour that has traditionally been difficult to diagnose in its early stages. Globally, up to 20,000 people die each year as a result of the disease.

The researchers say conventional techniques for distinguishing between benign and malignant asbestos-related disease are inaccurate, invasive and difficult for the mostly elderly with the illness.

Associate Professor Yates and her team analysed breath samples from 20 patients with malignant mesothelioma, along with 18 people with asbestos-related diseases and 42 control subjects in the study of which the results are published in the European Respiratory Journal.

In the study, patients with malignant disease, asbestos-related diseases and control patients were correctly identified in 88 per cent of cases.

The study authors say exhaled breath profiling can accurately distinguish between each of these groups of patients using the carbon polymer array , a technique that could eventually translate into a screening tool for high-risk populations.

Explore further: Study identifies new target in treating mesothelioma

Related Stories

Study identifies new target in treating mesothelioma

July 3, 2012
(Medical Xpress) -- An international team of researchers, led by Haining Yang, PhD, from the University of Hawai‘i Cancer Center, has identified HMGB1 as a critical protein in the pathogenesis of malignant mesothelioma, ...

Renal cancer drug temsirolimus shows promise against mesothelioma

May 1, 2011
A drug commonly used to treat kidney cancer may increase the effectiveness of chemotherapy for mesothelioma, according to a study published in the May issue of the Journal of Thoracic Oncology.

Recommended for you

Whole food diet may help prevent colon cancer, other chronic conditions

September 21, 2017
A diet that includes plenty of colorful vegetables and fruits may contain compounds that can stop colon cancer and inflammatory bowel diseases in pigs, according to an international team of researchers. Understanding how ...

New kinase detection method helps identify targets for developing cancer drugs

September 21, 2017
Purdue University researchers have developed a high-throughput method for matching kinases to the proteins they phosphorylate, speeding the ability to identify multiple potential cancer drug targets.

Poliovirus therapy induces immune responses against cancer

September 20, 2017
An investigational therapy using modified poliovirus to attack cancer tumors appears to unleash the body's own capacity to fight malignancies by activating an inflammation process that counter's the ability of cancer cells ...

Scientists restore tumor-fighting structure to mutated breast cancer proteins

September 20, 2017
Scientists at the Virginia Tech Carilion Research Institute have successfully determined the full architecture of the breast cancer susceptibility protein (BRCA1) for the first time. This three-dimensional information provides ...

Brain cancer growth halted by absence of protein, study finds

September 20, 2017
The growth of certain aggressive brain tumors can be halted by cutting off their access to a signaling molecule produced by the brain's nerve cells, according to a new study by researchers at the Stanford University School ...

New clinical trial explores combining immunotherapy and radiation for sarcoma patients

September 20, 2017
University of Maryland School of Medicine researchers are investigating a new approach to treat high-risk soft-tissue sarcomas by combining two immunotherapy drugs with radiation therapy to stimulate the immune system to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.